Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Beone Medicines Ltd. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$416.41+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
BeOne Medicines sells cancer medicines, chiefly BRUKINSA pills for blood cancers, to patients and health systems worldwide.
Company outlook: revenue of $6.9B to $7B for Fiscal year 2026 — up 30.1% on a year earlier